Once-versus twice-daily tacrolimus: Are the formulations truly equivalent?

Drugs

Volumn 71, Issue 12, 2011, Pages 1561-1577

  Barraclough, Katherine A ^a   Isbel, Nicole M ^a   Johnson, David W ^a   Campbell, Scott B ^a   Staatz, Christine E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Controlled release drugs; Liver transplant rejection; Renal transplant rejection; Tacrolimus.

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL (TOPIC); CONSTIPATION; COUGHING; CYTOMEGALOVIRUS INFECTION; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; FATIGUE; GASTROENTERITIS; GRAFT DYSFUNCTION; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOWER ABDOMINAL PAIN; MAXIMUM PLASMA CONCENTRATION; PARESTHESIA; PHARYNGITIS; POLYOMAVIRUS INFECTION; REVIEW; SINGLE DRUG DOSE; WOUND COMPLICATION;

DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 80051995539     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11593890-000000000-00000     Document Type: Review

References (60)

1. US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online]. Available from URL: http://www.ustransplant.org/an nual-reports/current/[Accessed 2010 Dec 20]
2. Australia and New Zealand Dialysis and Transplant Registry [online]. Available from URL: http://www.anzda ta.org.au/anzdata/AnzdataReport/33rdReport/ Ch08.pdf [Accessed 2010 Dec 20]
3. European Medicines Agency. Advagraf: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000712/human-med-000629.jsp&murl= menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 [Accessed 2010 Dec 20]
4. First MR. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit 2008 Apr; 30 (2): 159-66 (Pubitemid 351521642)
5. First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J 2004 Dec 31; 45 (6): 1127-31 (Pubitemid 40136672)
6. European Medicines Agency. Advagraf: scientific discussion [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000712/human-med-000629.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125 [Accessed 2010 Dec 20]
7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43 (10): 623-53 (Pubitemid 38981845)
8. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prografbased regimen to a once daily modified release tacrolimusbased regimen. Transplant Proc 2005 Mar; 37 (2): 867-70 (Pubitemid 40590728)
9. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prografbased regimen to a once-daily modified release tacrolimusbased regimen. Transplant Proc 2005 Mar; 37 (2): 1211-3 (Pubitemid 40590839)
10. Alloway R, Vanhaecke J, Undre N. Conversion of stable heart transplant recipients from twice daily prograf to once daily modified release tacrolimus. Transpl Int 2005; 18 Suppl. 1: 75
11. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year postconversion in stable pediatric liver transplant recipients. Am J Transplant 2007 Jun; 7 (6): 1609-15 (Pubitemid 46776251)
12. Diez Ojea B, Alonso Alvarez M, Aguado Fernandez S, et al. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc 2009 Jul-Aug; 41 (6): 2323-5
13. Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, et al. Conversion to tacrolimus extended-release formulation: short-term clinical results. Transplant Proc 2009 Jul-Aug; 41 (6): 2326-7
14. Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA, et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. Transplant Proc 2009 Jul-Aug; 41 (6): 2184-6
15. de Jonge H, Kuypers DR, Verbeke K, et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010 Sep 15; 90 (5): 523-9
16. Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011 Apr; 21 (4): 179-84
17. Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. Transplant Proc 2010May; 42 (4): 1322-4
18. Marzoa-Rivas R, Paniagua-Martin MJ, Barge-Caballero E, et al. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. Transplant Proc 2010 Oct; 42 (8): 2994-6
19. Mecule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc 2010 May; 42 (4): 1317-9
20. Comuzzi C, Lorenzin D, Rossetto A, et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. Transplant Proc 2010 May; 42 (4): 1320-1
21. Iaria G, Sforza D, Angelico R, et al. Switch from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (advagraf) in kidney transplantation. Transplant Proc 2011 May; 43 (4): 1028-9
22. Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011 Mar 15; 91 (5): 566-9
23. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. London: European Medicines Agency; 2010 Jan 20, p. 16 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/qwp/140198enrev1fin.pdf [Accessed 2011 Apr 26]
24. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009 Nov; 9 (11): 2505-13
25. Undre NA. Use of a once daily modified release tacrolimus regimen in de novo liver transplant recipients [abstract no. 859]. Am J Transplant 2005; 5 Suppl. 5: 374
26. Kramer BK, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010 Dec; 10 (12): 2632-43
27. Andres A, Delgado-Arranz M, Morales E, et al. Extendedrelease tacrolimus therapy in de novo kidney transplant recipients: single-center experience. Transplant Proc 2010 Oct; 42 (8): 3034-7
28. Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009 Jul-Aug; 41 (6): 2115-7
29. Jelassi ML, Lefeuvre S, Karras A, et al. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. Transplant Proc 2011 Mar; 43 (2): 491-4
30. Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twicedaily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010 Oct; 10 (10): 2313-23
31. Silva Jr HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007 Mar; 7 (3): 595-608 (Pubitemid 46376444)
32. Cabello M, Garcia P, Gonzalez-Molina M, et al. Pharmacokinetics of once-versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc 2010 Oct; 42 (8): 3038-40
33. Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit 2010 Apr; 32 (2): 129-35
34. Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010Oct 1; 49 (10): 683-92
35. Canaparo R, Finnstrom N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007 Nov; 34 (11): 1138-44 (Pubitemid 47416351)
36. Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011 Jul 1; 50 (7): 451-9
37. van Hooff JP, Alloway RR, Trunecka P, et al. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant 2011 Jan-Feb; 25 (1): E1-12
38. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007 Jun 27; 83 (12): 1639-42 (Pubitemid 46987918)
39. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007 Jun 27; 83 (12): 1648-51 (Pubitemid 46987920)
40. Heffron TG. A two year follow-up of stable pediatric liver transplant recipients converted from a twice daily Prograf based regimen to a once daily extended release tacrolimus based regimen [abstract no. 777]. Am J Transplant 2007; Suppl. 2: 348
41. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999 Apr 27; 67 (8): 1133-7 (Pubitemid 29205575)
42. Ishibashi M, Yoshida K, Ozono S, et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). Transplant Proc 2001 Feb-Mar; 33 (1-2): 559-60 (Pubitemid 32237514)
43. Tada H, Satoh S, IinumaM, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003 Aug; 43 (8): 859-65 (Pubitemid 36886106)
44. Braun F, Schutz E, Peters B, et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 2001 May; 33 (3): 2127-8 (Pubitemid 33762655)
45. Kimikawa M, Kamoya K, Toma H, et al. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001 Oct; 15 (5): 324-9 (Pubitemid 32936879)
46. Pisitkun T, Eiam-Ong S, Chusil S, et al. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002 Dec; 34 (8): 3173-5 (Pubitemid 35463284)
47. Bottiger Y, Undre NA, Sawe J, et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc 2002 Aug; 34 (5): 1544-5
48. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000 Apr; 35 (4): 660-6
49. Stolk LM, Van Duijnhoven EM, Christiaans MH, et al. Trough levels of tacrolimus [letter]. Ther Drug Monit 2002 Aug; 24 (4): 573;author reply 573-4
50. Mathew BS, Fleming DH, Jeyaseelan V, et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol 2008 Oct; 66 (4): 467-72
51. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995 Mar; 57 (3): 281-90
52. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002 Aug; 17 (8): 1487-90
53. Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc 1998 Jun; 30 (4): 1460-1 (Pubitemid 28309644)
54. Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 2005 Aug; 27 (4): 431-4 (Pubitemid 41098816)
55. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009 Apr; 31 (2): 139-52
56. Woillard JB, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations: twice daily prograf and once daily advagraf. Br J Clin Pharmacol 2011 Mar; 71 (3): 391-402
57. Woywodt A, Delargy M, Thain Z. Different preparations of tacrolimus and medication errors [letter]. Am J Transplant 2008 Sep; 8 (9): 1962
58. Tacrolimus (Advagraf and Prograf): risk of serious medication errors. Drug Saf Update 2009 Jan; 2 (6): 4-5 [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?IdcService=GET-FILE&dDocName= CON035990& RevisionSelectionMethod=Latest [Accessed 2010 Dec 20]
59. European Medicines Agency, Committee for Medicinal Products for Human Use. November 2008 plenary meeting monthly report. London: European Medicines Agency; 2008 Nov 27. p 3 [online]. Available from URL: http://www. emea.europa.eu/pdfs/human/press/pr/61207408en.pdf [Accessed 2010 Dec 20]
60. The Institute for Safe Medication Practices Canada. Prograf andAdvagrafmix-up. Can J Hosp Pharm2009; 62 (5): 417-8